MG
ACRS icon

Marex Group’s Aclaris Therapeutics ACRS Stock Holding History

Marex Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,400
Closed -$20.4K – 847
2025
Q2 		$20.4K Hold
14,400
– – ﹤0.01% 622
2025
Q1 		$22K Hold
14,400
– – ﹤0.01% 662
2024
Q4 		$35.7K Hold
14,400
– – ﹤0.01% 649
2024
Q3 		$16.6K Hold
14,400
– – ﹤0.01% 580
2024
Q2 		$15.8K Hold
14,400
– – ﹤0.01% 618
2024
Q1 		$17.9K Hold
14,400
– – ﹤0.01% 461
2023
Q4 		$15.1K Buy
+14,400
New +$43.9K ﹤0.01% 545

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Marex Group's ACRS Position: Q3 2025 in Review

Marex Group sold out of Aclaris Therapeutics (ACRS) in Q3 2025, closing a stake of 14,400 shares — an estimated $20.4K sold.

Marex Group first reported a position in ACRS in Q4 2023 and held it in 7 quarters. The position peaked at $35.7K in Q4 2024. 103 funds tracked by Wall St. Rank hold ACRS as of Q3 2025.

  • Marex Group reported no remaining Aclaris Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Marex Group sold 14,400 Aclaris Therapeutics shares in Q3 2025, an estimated $20.4K.
  • Marex Group first reported a position in Aclaris Therapeutics in Q4 2023 and held it in 7 quarters.
  • Marex Group's Aclaris Therapeutics position peaked at $35.7K in Q4 2024.
  • 103 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2025.

Based on Marex Group's 13F filing for Q3 2025, filed 14 Nov 2025.